Tonix Pharmaceut Stock Price, News & Analysis

Tonix Pharmaceuticals (Nasdaq: TNXP) announced plans to present two posters at the 2021 ASCP Annual Meeting from June 1-4, 2021. The presentations will focus on TNX-102 SL for treating fibromyalgia and PTSD, showcasing results from their clinical trials. The first poster, on June 2, will detail a Phase 3 trial's positive results in fibromyalgia, while the second, on June 3, will analyze PTSD outcomes. Tonix aims to release interim data from its second Phase 3 study in Q3 2021 and topline data in Q1 2022.

Tonix Pharmaceuticals (Nasdaq: TNXP) announced that CEO Seth Lederman will present at the Q2 Investor Summit Virtual Conference on May 17, 2021, at 3:30 p.m. ET. Investors can arrange virtual meetings with management through the conference coordinator. Tonix focuses on developing therapies for CNS and immunology, with lead candidates including TNX-102 SL for fibromyalgia and TNX-1800, a COVID-19 vaccine. Positive data from animal studies of TNX-1800 were reported in early 2021. Interim data from the RALLY study is expected in Q3 2021.

Tonix Pharmaceuticals (Nasdaq: TNXP) reported Q1 2021 financial results, achieving a cash balance of approximately $164 million, up from $77.1 million at the end of 2020. The company experienced a net loss of $20.7 million, or $0.07 per share, compared to $9 million a year prior. Key updates include positive animal study results for its COVID-19 vaccine candidate TNX-1800 and ongoing development of its CNS programs, with three entering Phase 2 trials this year. An interim analysis for its fibromyalgia treatment, TNX-102 SL, is expected in Q3 2021.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that CEO Seth Lederman will present and join a panel discussion at the 4th Annual Neuroscience Innovation Forum, taking place April 28-30, 2021.

The panel, titled Pain, Migraine & Addiction, is scheduled for April 29 from 11:45 a.m. to 12:45 p.m. ET. The presentation will be available on demand during the event and afterwards on the Tonix website. Tonix focuses on developing therapies for CNS conditions, with key candidates like TNX-102 SL for fibromyalgia.

Tonix Pharmaceuticals (Nasdaq: TNXP) has entered a global licensing agreement with OyaGen for TNX-3500 (sangivamycin), an antiviral drug targeting SARS-CoV-2. Initial studies indicate TNX-3500 exhibits approximately 65 times greater potency than remdesivir against SARS-CoV-2 and shows additive effects when combined with it. This drug is in pre-Investigational New Drug (IND) development and has demonstrated safety in previous human studies. Tonix aims to advance TNX-3500 for regulatory approval in treating COVID-19.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that CEO Seth Lederman will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 8:00 a.m. ET. Investors can arrange virtual meetings through the conference coordinator. Tonix focuses on CNS and immunology treatments, with its lead CNS candidate, TNX-102 SL, in mid-Phase 3 for fibromyalgia. Positive efficacy data for its COVID-19 vaccine candidate, TNX-1800, was reported, while interim data for the RALLY trial is expected in Q3 2021.

Tonix Pharmaceuticals (Nasdaq: TNXP) announced plans to initiate a Phase 2 Clinical Trial for TNX-601 CR, a novel treatment for Major Depressive Disorder (MDD), pending toxicology study results. Following a recent FDA Type B meeting, the company aims to submit an IND for a human abuse potential study. TNX-601 CR incorporates naloxone to deter misuse. With tianeptine sodium’s established efficacy, TNX-601 CR promises once-daily dosing, potentially improving patient adherence. The company emphasizes its unique mechanism differs from currently approved antidepressants.

Tonix Pharmaceuticals (Nasdaq: TNXP) announced the issuance of U.S. Patent No. 10,946,027 on March 16, 2021, for its development candidate TNX-601 CR, a controlled-release tablet containing tianeptine oxalate and naloxone. This patent grants market exclusivity until December 28, 2037, supporting the development of TNX-601 CR for treating major depressive disorder and PTSD. The formulation is designed for once-daily dosing, enhancing patient adherence compared to existing products. The patent signifies a major advancement in Tonix's proprietary drug development efforts.

Tonix Pharmaceuticals announced promising preliminary results for its COVID-19 vaccine candidate TNX-1800 in non-human primates. In a study, all eight vaccinated animals had no detectable SARS-CoV-2 in their airways after being challenged. TNX-1800, based on a horsepox vector, aims to provide long-term T cell immunity. Vaccination results indicated strong neutralizing antibody response and confirmed the 'take' as a biomarker for immunity. The company plans to advance TNX-1800 to human Phase 1 trials in late 2021, following FDA clearance and production of GMP-quality material.